Last $2.97 USD
Change Today +0.0217 / 0.74%
Volume 11.5K
CLRB On Other Exchanges
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

cellectar biosciences inc (CLRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/2/14 - $9.20
52 Week Low
09/9/14 - $2.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cellectar biosciences inc (CLRB) Related Businessweek News

No Related Businessweek News Found

cellectar biosciences inc (CLRB) Details

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

cellectar biosciences inc (CLRB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: $180.3K
Vice President of Business Development
Total Annual Compensation: $195.8K
Compensation as of Fiscal Year 2013.

cellectar biosciences inc (CLRB) Key Developments

Cellectar Biosciences, Inc. Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma

Cellectar Biosciences, Inc. announced that the U.S. Food & Drug Administration (FDA) has accepted the company's investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells. I-131-CLR1404 is radiotherapeutic comprised of a proprietary phospholipid ether (PLE) analog, acting as a cancer-targeted delivery and retention vehicle, covalently labeled with Iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer types. Because Cellectar's PLE platform has been shown to reliably and universally accumulate in malignant cancer cells, and the therapeutic properties of the Iodine-131 isotope are well known, I-131-CLR1404 is engineered to combine an intracellular radiation mechanism of destroying cancer cells, including cancer stem cells, through targeted delivery specific to malignant tissue that spares critical normal tissues from consequential radiation dose. Cellectar plans to initiate a Phase I/II, proof-of-concept trial during the fourth quarter 2014 in approximately 20 patients with relapsed or refractory multiple myeloma that have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. The primary objective of the study will be to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone. In addition, the trial will seek to identify the recommended dose for future pivotal trials and determine therapeutic activity of I-131-CLR1404 in this patient population as measured by overall response rate, time to progression and duration of response.

Cellectar Biosciences, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 02:30 PM

Cellectar Biosciences, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 02:30 PM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Simon C. Pedder, Chief Executive Officer, President and Director.

Cellectar Biosciences, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Cellectar Biosciences, Inc. reported financial results for the second quarter and six months ended June 30, 2014. The company reported a net loss for the quarter ended June 30, 2014 of approximately $2.1 million or $0.73 per share in line with the net loss of $2.1 million or $0.72 per share reported for the comparable period in 2013. For the first six months of 2014, The company reported a net loss of $5.0 million or $1.75 per share compared to a net loss of $5.5 million or $2.03 per share for the first half of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRB:US $2.97 USD +0.0217

CLRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLRB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTAR BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at